

## ATTACHMENT FINANCIAL NEWS 2026

### **Remgro to restructure shared interests in Mediclinic**

In April **Business Day** reported that Remgro and Investment Holding Limited (IHL) plan to restructure their shared interests in Mediclinic Holdings. This will result in Remgro becoming the sole owner of Mediclinic Southern Africa (MCSA). IHL would take 100% of Hirslanden, Mediclinic's Swiss business.

In June **Daily Investor** reported that the Competition Tribunal has approved Remgro's acquisition of Mediclinic International, giving the investment giant sole ownership over the Intercare group of companies and ER24 EMS. Prior to the deal, IHL and Remgro were co-shareholders in Mediclinic Holdings, holding 50% of the company's issued shares each. – **Daily Investor** (11 June 2026)

### **Court orders release of medical records in listeriosis case**

The Gauteng High Court ordered the release of confidential medical records to the legal team of 16 claimants in the listeriosis class action against Tiger Brands.

“Meanwhile, a supplier to a major national supermarket is likely to be slapped with a R1m fine for listeria-contaminated products that resulted in a massive recall in March 2018,” reported **Medical Brief** (22 April 2026)

The application was aimed against the National Health Laboratory Service, the Minister of Health and Tiger Brands-related entities.

At least 218 lives were lost to the 2017 outbreak, linked to the Tiger Brands Enterprise processing facility in Polokwane and the class action – involving hundreds of people who claimed they became ill or lost loved ones from contaminated food – has been lingering for several years.

Tiger Brands has presented settlement offers to several claimants.

### **Biovac retains contract to supply Hexaxim**

Biovac has retained a R5.3bn contract to supply the State with *Hexaxim*, the six-in-one shot for infants in the national childhood immunisation programme. – **Business Day** (14 May 2026) The tender is set to begin on 1 January 2027.

The contract is vital to Biovac's financial stability as it relies heavily on state business for its ongoing operations. In 2023 Biovac had to retrench staff after the Department of Health rejected its pneumonia vaccine in favour of cheaper imported alternatives from India.

The local subsidiary of Indian generic drug manufacturer, Cipla, won contracts worth a combined R1.1bn to supply vaccines against pneumonia, rotavirus and hepatitis.

### **Netcare patient growth may slow down due to GEMS changes**

GEMS, SA's largest medical scheme for public servants, is expected to reduce patient volumes at private hospitals, particularly among members of the scheme's popular Tanzanite One option. This has lowered growth expectations of private

hospital group Netcare for the year to 30 September 2026.

Netcare CEO Richard Friedland also warned that the US-Iran war could create additional pressure for the business due to the effect of higher fuel prices. Netcare expects to spend an extra R10m on fuel over the next six months. – **Business Day** (26 May 2026)

### ***HIV funding cuts cripple HIV drug distribution***

A report by Physicians for Human Rights warns that US HIV funding cuts under the Trump administration are crippling the systems necessary for SA's HIV drug distribution. Reduced support, particularly through the President's Emergency Plan for AIDS Relief (PEPFAR), has weakened critical delivery systems needed to distribute *lenacapavir*, a highly effective twice-yearly prevention injection. Despite SA receiving initial doses, experts say infrastructure collapse threatens implementation. **Business Day** (23 April 2026)